Molecular Screening Improves Colorectal Cancer Triage
New testing methods help patients in Latin America prioritize colonoscopies by identifying high-risk individuals earlier.
Updated on Oct. 22, 2026 in Cancer
Live Poll
Do you believe non-invasive screening tests effectively improve patient access to care in your area?
Health systems in Latin America are utilizing stool-based molecular screening tests to identify colorectal cancer risk factors. This approach acts as a gatekeeper to help prioritize colonoscopies in regions where specialist and endoscopy resources are limited.
Why it matters
In Latin America, where colorectal cancer is the second-most common malignant neoplasm, the current median interval from symptom onset to treatment reaches 7 months. Expanding molecular screening helps manage infrastructure gaps by streamlining access for patients with the highest clinical need.
Clinical performance data shows that 80% of individuals with positive stool-based screening results are found to have confirmed colorectal abnormalities upon follow-up. The long-term impact of this triage model on regional mortality rates remains under investigation.
The players
BGI Genomics
A biotechnology firm based in Shenzhen, China, that provides genetic testing and sequencing services to 2,300 medical institutions globally.
The details
The testing technology works by identifying hypermethylation across three specific biomarkers: SDC2, ADHFE1, and PPP2R5C. These molecular assays detect cellular alterations associated with precancerous adenomas. Because the process is non-invasive and requires no bowel preparation, fasting, or sedation, it allows health systems to better allocate limited endoscopy suites and specialist gastroenterologist time to those at highest risk.
Timeline
2014-2026: FDA approved multiple advanced molecular tests.
July 2017: BGI Genomics began trading on the Shenzhen Stock Exchange.
Health Landscape
The adoption of molecular gatekeeping in Latin American colorectal screening follows a pattern set by the broader global shift toward using biomarker-based triage to prioritize endoscopy resources. This transition addresses critical infrastructure shortages in diagnostic oncology.
If you are concerned about digestive health, consider asking your physician if a non-invasive molecular screening test is an appropriate initial step for your risk profile. This conversation is particularly relevant in areas where specialist access is limited and wait times for traditional procedures are long.
The takeaway
Molecular screening can provide a practical pathway to prioritize care when endoscopy access is limited. If you have concerns about colorectal cancer risk, discuss whether a non-invasive screening test or a traditional colonoscopy is the right starting point for your health care plan.
Further reading
For more on emerging tools for early detection, visit Cancer.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe non-invasive screening tests effectively improve patient access to care in your area?
